BCA
IBRX icon

Bay Colony Advisors’s ImmunityBio IBRX Stock Holding History

Bay Colony Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Sell
12,750
-2,250
-15% -$17K 0.01% 483
2026
Q1 		$115K Buy
+15,000
New +$103K 0.01% 480

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bay Colony Advisors's IBRX Position: Q2 2026 in Review

Bay Colony Advisors reduced its ImmunityBio (IBRX) stake by 15% in Q2 2026, selling an estimated $17K and leaving 12,750 shares worth $112K. The position accounts for 0.01% of the portfolio, ranked #483.

Bay Colony Advisors first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $115K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Bay Colony Advisors held 12,750 shares of ImmunityBio worth $112K as of Q2 2026.
  • Bay Colony Advisors sold 2,250 ImmunityBio shares in Q2 2026, an estimated $17K.
  • ImmunityBio made up 0.01% of Bay Colony Advisors's portfolio in Q2 2026, its #483 holding.
  • Bay Colony Advisors first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • Bay Colony Advisors's ImmunityBio position peaked at $115K in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Bay Colony Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.